932721.fig.002a
(a)
932721.fig.002b
(b)
932721.fig.002c
(c)
932721.fig.002d
(d)
932721.fig.002e
(e)
932721.fig.002f
(f)
Figure 2: Median reductions from baseline over time in anti-TNF treated patients of (a) active joint count (AJC); (b) psoriasis area severity index (PASI); (c) health assessment quality (HAQ); (d) dermatology life quality index (DLQI); (e) Visual Analogic Scales (VAS) pain; and (f) visual analogic scales (VAS) itch.